TY  - JOUR
AU  - Patti, Francesco
AU  - Grazia-Chisari, Clara 
AU  - Fernandez, Oscar
AU  - Sarroca, Jorge
AU  - Ferrer-Picon, Elena
AU  - Hernandez-Vicente, Francisco
AU  - Vila-Silvan, Carlos
PY  - 2022
DO  - 10.1111/ene.15412
UR  - http://hdl.handle.net/10668/19955
T2  - European journal of neurology
AB  - Nabiximols is a therapeutic option for patients with multiple sclerosis (MS) spasticity whose symptoms are poorly controlled by conventional oral first-line medications. This study aimed to assess the relationship between changes in spasticity...
LA  - en
PB  - John Wiley & Sons
KW  - e-Registry analysis
KW  - Multiple sclerosis
KW  - Nabiximols
KW  - Spasticity-plus syndrome
KW  - Spasticity-related symptoms
KW  - Cannabidiol
KW  - Central Nervous System Diseases
KW  - Dronabinol
KW  - Drug Combinations
KW  - Humans
KW  - Multiple Sclerosis
KW  - Muscle Cramp
KW  - Muscle Spasticity
KW  - Pain
KW  - Spasm
KW  - Treatment Outcome
TI  - A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
TY  - research article
VL  - 29
ER  -